4//SEC Filing
Valeant Pharmaceuticals International, Inc. 4
Accession 0000885590-14-000021
$BHCCIK 0000885590operating
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 4:43 PM ET
Size
9.3 KB
Accession
0000885590-14-000021
Insider Transaction Report
Form 4
Weldon Ryan
EVP, Company Group Chairman
Transactions
- Exercise/Conversion
Common Stock, no par value
2014-02-11+11,000→ 103,823 total - Tax Payment
Common Stock, no par value
2014-02-11−5,707→ 98,116 total - Exercise/Conversion
Restricted Share Units
2014-02-11−11,000→ 11,000 total→ Common Stock (11,000 underlying)
Footnotes (2)
- [F1]This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $62.62 starting on January 28, 2013 and the average stock price for the 20 trading days starting on each measurement dates: 25% on October 28, 2015, 50% on January 28, 2016 and 25% on April 28, 2016. Unit vesting is contingent on TSR performance between 10% and 30% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The PSU award may still payout two times grant value.
- [F2]This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Performance Share Units.
Documents
Issuer
Valeant Pharmaceuticals International, Inc.
CIK 0000885590
Entity typeoperating
IncorporatedNJ
Related Parties
1- filerCIK 0000885590
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 4:43 PM ET
- Size
- 9.3 KB